Ireland· IE-PA-EU/1/10/646/002-006
VPRIV 400 Units powder for solution for infusion
A velaglucerase alfa product containing velaglucerase alfa, registered in Ireland by Shire Pharmaceuticals Ireland Limited. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Velaglucerase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB10 (velaglucerase alfa), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Velaglucerase alfa · ATC A16AB10
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Velaglucerase alfa
- Manufacturer
- Shire Pharmaceuticals Ireland Limited
- Country
- Ireland (IE)
- ATC code
- A16AB10
- ATC class
- Velaglucerase alfa
- Defined daily dose
- 300 E, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/10/646/002-006
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Velaglucerase alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVprivShire Pharmaceuticals Ireland Ltd.
- CzechiaVPRIVTakeda Pharmaceuticals International AG Ireland Branch, Dublin
- SwedenVPRIV 200 E Pulver till infusionsvätska, lösningShire Pharmaceuticals Ireland Limited
- BelgiumVpriv 200 IUShire Pharmaceuticals Ireland
- FranceVPRIV 400 unités, poudre pour solution pour perfusionTAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE)
- United KingdomVPRIV 400units powder for solution for infusion vialsTakeda UK Ltd
- IcelandVPRIVTakeda Pharmaceuticals International AG Ireland Branch
- Japanベラグルセラーゼ アルファ（遺伝子組換え）武田薬品工業
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vpriv
- Liechtenstein · Vpriv
- Norway · Vpriv
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dab3be69-be32-4569-8d0e-ab933a053e7f GET /v1/drugs/dab3be69-be32-4569-8d0e-ab933a053e7f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"A16AB10"
],
"strength": null,
"pa_number": "EU/1/10/646/002-006",
"substances": [
"Velaglucerase alfa"
],
"legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about velaglucerase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.